Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDegAsp twice daily versus NovoMix 30 twice daily added to metformin in insulin-naive adults with type 2 diabetes
2011-001712-61Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2011
- Modality
- Small Molecules, Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing IDegAsp BID + metformin with BIAsp 30 BID + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c after 26 weeks. Started Aug 2011; status: completed.
02
Drugs
insulin degludec + insulin aspartbiphasic insulin aspartmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001712-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001712-61.